Fortis Healthcare Ltd. FORTIS
NSE · India · Health Services
INR 785.00+15.00 (+1.95%)
Market open· · INR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · INR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Fortis Healthcare, part of the IHH Healthcare group, today announced plans to install the MEVION S250-FIT™ Proton Therapy System™ from Mevion Medical Systems at Fortis Memorial Research Institute (FMRI), Gurugram, its flagship quaternary-care hospital and a leading centre for comprehensive oncology and precision cancer care.
Fortis Healthcare Ltd (BOM:532843) reports strong top-line growth driven by hospital business, while navigating margin headwinds from new facilities and strategic investments.
Fortis Healthcare Ltd (BOM:532843) reports robust financial performance with significant revenue growth and strategic initiatives driving future prospects.
Novo Nordisk's semaglutide patent expires March 20 as Indian drugmakers prepare lower-cost versions and hospitals expand obesity clinics.
Fortis Healthcare Ltd (BOM:532843) reports a robust 17.3% revenue increase, while navigating weather disruptions and strategic expansions.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.